Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
20 Jun 2024
20 Jun 2024
Historique:
revised:
29
04
2024
received:
05
02
2024
accepted:
30
05
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
20
6
2024
Statut:
aheadofprint
Résumé
Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax-azacitidine due to poor tolerance. Sixty-two newly diagnosed (ND) AML patients and 22 patients with morphological relapse or refractory AML were included. In the ND cohort (n = 62), 28 patients stopped venetoclax and azacitidine and 34 patients continued azacitidine monotherapy. With a median follow-up of 23 months (IQR, 20-32), median overall survival and treatment-free survival were 44 (IQR, 16-NR) and 16 (IQR, 8-27) months, respectively. Patients who stopped both treatments and those who continued azacitidine monotherapy had the same outcomes. Negative minimal residual disease was associated with a 2-year treatment-free survival of 80%. In the RR cohort (n = 22), median overall survival and treatment-free survival were 19 (IQR, 17-31) and 10 (IQR, 5-NR) months, respectively. Prior number of venetoclax-azacitidine cycles and IDH mutations were associated with increased overall survival. The only factor significantly impacting treatment-free survival was the number of prior cycles. This study suggests that patients who discontinued treatment in remission have favorable outcomes supporting the rationale for prospective controlled trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
Références
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136‐1152.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424‐447.
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200‐1228.
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291‐299.
Schuh AC, Döhner H, Pleyer L, Seymour JF, Fenaux P, Dombret H. Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol. 2017;116:159‐177.
Récher C, Röllig C, Bérard E, et al. Long‐term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2022;36(4):913‐922.
Pollyea DA, DiNardo CD, Arellano ML, et al. Impact of Venetoclax and Azacitidine in treatment‐Naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28(13):2753‐2761.
Gangat N, Karrar O, Iftikhar M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99(2):193‐202.
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617‐629.
Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment‐Naïve acute myeloid leukemia with Venetoclax and Azacitidine. J Clin Oncol. 2022;40(8):855‐865.
Maiti A, DiNardo CD, Wang SA, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021;5(7):1876‐1883.
Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo‐controlled trial. Blood. 2020;135(24):2137‐2145.
Othman J, Tiong IS, O'Nions J, et al. Molecular MRD is strongly prognostic in patients with NPM1‐mutated AML receiving venetoclax‐based non‐intensive therapy. Blood. 2023;143(4):336‐341.
Chua CC, Hammond D, Kent A, et al. Treatment‐free remission after ceasing venetoclax‐based therapy in patients with acute myeloid leukemia. Blood Adv. 2022;6(13):3879‐3883.
Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost‐effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021;5(4):994‐1002.
Cho SK, Manzoor BS, Sail KR, et al. Budget impact of 12‐month fixed treatment duration Venetoclax in combination with Obinutuzumab in previously untreated chronic lymphocytic leukemia patients in the United States. Pharmacoeconomics. 2020;38(9):941‐951.
Blombery P, Lew TE, Dengler MA, et al. Clonal hematopoiesis, myeloid disorders and BAX‐mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2022;139(8):1198‐1207.
Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of Venetoclax‐rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post‐treatment follow‐up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269‐277.
Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029‐1035.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391‐2405.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377.
Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood. 2021;138(26):2753‐2767.
Pratz KW, Jonas BA, Pullarkat VA, et al. Long‐term follow‐up of the phase 3 Viale‐a clinical trial of Venetoclax plus Azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Blood. 2022;140(Supplement 1):529‐531.
Ravandi F, Cloos J, Buccisano F, et al. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: roadmap from an ELN‐DAVID expert panel. Am J Hematol. 2023;98(12):1847‐1855.